In recent years, obesity has been linked with cancer by an epidemic study and is associated with 14% (men) to 20% (women) of all cancer deaths. 1 Therefore, it is urgent to elucidate the mechanism(s) by which obesity increases the incidence of cancer. Several factors altered in obesity have been identified to be associated with the increased risk of cancer. They include increased blood levels of insulin, insulin-like growth factor 1, leptin, tumor necrosis factor a and interleukin (IL)-6, and decreased blood level of adiponectin. 2 5 Src is a cellular protein encoded by an oncogene that can promote cancer formation and metastasis. 6 Thus, inhibitors of Src have been developed for the treatment of several cancers. Src activates both the phosphoinositide kinase-3 (PI3K)/Akt pathway and cytoskeleton for the carcinogenesis. 6 The PI3K/Akt pathway has been shown to be activated in many cancers and has important roles in the carcinogenesis and prognosis, through a cascade of downstream targets such as the mammalian target of rapamycin, nuclear factor-kB and Bcl2, which promote cell proliferation, cell growth and decrease apoptosis. 2 The inhibitors of the PI3K/Akt activity have been developed for the treatment of cancer and have entered clinical use rapidly. 7, 8 These agents include PI3K inhibitors, the Akt inhibitor and the mammalian target of rapamycin inhibitor, as well as dual inhibitors of PI3K and the mammalian target of rapamycin. 8 Mitogenactivated protein kinase is also a carcinogenic pathway, which converts extracellular stimuli into cell growth, proliferation and invasion. 8 In addition, IL-17 also promotes cancer formation via the signal transducer and activator of transcription 3. 4,9 Therefore, it could be interesting to further investigate the role of IL-17 in obesity-associated cancer and also whether the blockage of this cytokine and associated signal pathways can have preventive and therapeutic implications in obesity-associated cancer.
